Cornel Iridoid Glycoside Suppresses Hyperactivity Phenotype in rTg4510 Mice through Reducing Tau Pathology and Improving Synaptic Dysfunction

Abstract

rTg4510 mice are transgenic mice expressing P301L mutant tau and have been developed as an animal model of tauopathies including Alzheimer’s disease (AD). Besides cognitive impairments, rTg4510 mice also show abnormal hyperactivity behavior. Cornel iridoid glycoside (CIG) is an active ingredient extracted from Cornus officinalis, a traditional Chinese herb. The purpose of the present study was to investigate the effects of CIG on the emotional disorders such as hyperactivity, and related mechanisms. The emotional hyperactivity was detected by locomotor activity test and Y maze test. Immunofluorescent and immunohistochemical analyses were conducted to measure neuron loss and phosphorylated tau. Western blotting was used to detect the expression of related proteins. The results showed that intragastric administration of CIG for 3 months decreased the hyperactivity phenotype, prevented neuronal loss, reduced tau hyperphosphorylation and aggregation in the amygdala of rTg4510 mice. Meanwhile, CIG alleviated the synaptic dysfunction by increasing the expression of N-methyl-D-aspartate receptors (NMDARs) subunits GluN1 and GluN2A and αamino-3-hydroxy-5-methyl-4-isoxazole propionic acid receptor (AMPAR) subunits GluA1 and GluA2, and increased the level of phosphorylated Ca²⁺/calmodulin dependent protein kinase II α (p-CaMK IIα) in the brain of rTg4510 mice. In conclusion, CIG may have potential to treat the emotional disorders in tauopathies such as AD through reducing tau pathology and improving synaptic dysfunction.

Keywords

cornel iridoid glycoside / rTg4510 mouse / hyperactivity / tauopathy / Alzheimer’s disease / tau phosphorylation / synaptic function

References

[1] IqbalK, LiuF, GongCX. Tau and neurodegenerative disease: the story so far. Nat Rev Neurol, 2016, 12(1): 15-27

[2] TatsumiH, NakaakiS, ToriiK, et al.. Neuropsychiatric symptoms predict change in quality of life of Alzheimer disease patients: a two-year follow-up study. Psychiatry Clin Neurosci, 2009, 63(3): 374-384

[3] Pena-CasanovaJ, Sanchez-BenavidesG, de SolaS, et al.. Neuropsychology of Alzheimer’s disease. Arch Med Res, 2012, 43(8): 686-693

[4] BergerZ, RoderH, HannaA, et al.. Accumulation of pathological tau species and memory loss in a conditional model of tauopathy. J Neurosci, 2007, 27(14): 3650-3662

[5] SantacruzK, LewisJ, SpiresT, et al.. Tau Suppression in a Neurodegenerative Mouse Model Improves Memory Function. Science, 2005, 309(5733): 476-481

[6] KopeikinaK J, PolydoroM, TaiH, et al.. Synaptic alterations in the rTg4510 mouse model of tauopathy. J Comp Neurol, 2013, 521(6): 1334-1353

[7] JulP, VolbrachtC, de JongIEM, et al.. Hyperactivity with agitative-like behavior in a mouse tauopathy model. J Alzheimer Dis, 2015, 49(3): 783-795

[8] BrownlowML, Joly-AmadoA, AzamS, et al.. Partial rescue of memory deficits induced by calorie restriction in a mouse model of tau deposition. Behav Brain Res, 2014, 271: 79-88

[9] CookC, DunmoreJH, MurrayME, et al.. Severe amygdala dysfunction in a MAPT transgenic mouse model of frontotemporal dementia. Neurobiol Aging, 2014, 35(7): 1769-1777

[10] KoppelJ, JimenezH, AzoseM, et al.. Pathogenic tau species drive a psychosis-like phenotype in a mouse model of Alzheimer’s disease. Behav Brain Res, 2014, 275: 27-33

[11] MaD, WangN, FanX, et al.. Protective effects of cornel iridoid glycoside in rats after traumatic brain injury. Neurochem Res, 2018, 43(4): 959-971

[12] MaD, ZhuY, LiY, et al.. Beneficial effects of cornel iridoid glycoside on behavioral impairment and senescence status in SAMP8 mice at different ages. Behav Brain Res, 2016, 312: 20-29

[13] MaD, LuoY, HuangR, et al.. Cornel iridoid glycoside suppresses tau hyperphosphorylation and aggregation in a mouse model of tauopathy through increasing activity of PP2A. Curr Alzheimer Res, 2019, 16(14): 1316-1331

[14] YaoR Q, ZhangL, WangW, et al.. Cornel iridoid glycoside promotes neurogenesis and angiogenesis and improves neurological function after focal cerebral ischemia in rats. Brain Res Bull, 2009, 79(1): 69-76

[15] FolchJ, BusquetsO, EttchetoM, et al.. Memantine for the Treatment of Dementia: A Review on its Current and Future Applications. J Alzheimer Dis, 2018, 62(3): 1223-1240

[16] DaiC, HuW, TungYC, et al.. Tau passive immunization blocks seeding and spread of Alzheimer hyperphosphorylated Tau-induced pathology in 3 × Tg-AD mice. Alzheimers Res Ther, 2018, 10(1): 1-14

[17] ZhangY, LiP, FengJ, et al.. Dysfunction of NMDA receptors in Alzheimer’s disease. Neurol Sci, 2016, 37(7): 1039-1047

[18] ApiccoDJ, AshPEA, MaziukB, et al.. Reducing the RNA binding protein TIA1 protects against tau-mediated neurodegeneration in vivo. Nat Neurosci, 2018, 21(1): 72-80

[19] HuangH, NieS, CaoM, et al.. Characterization of AD-like phenotype in aged APPSwe/PS1dE9 mice. AGE, 2016, 38(4): 303-322

[20] YoshikawaM, SoedaY, MichikawaM, et al.. Tau depletion in APP transgenic mice attenuates task-related hyperactivation of the hippocampus and differentially influences locomotor activity and spatial memory. Front Neurosci-Switz, 2018, 12: 124

[21] Cohen-MansfieldJ, BilligN. Agitated behaviors in the elderly. I. A conceptual review. J Am Geriatr Soc, 1986, 34(10): 711-721

[22] KongEH. Agitation in dementia: concept clarification. J Adv Nurs, 2005, 52(5): 526-536

[23] Millan-CalentiJC, Lorenzo-LópezL, Alonso-BúaB, et al.. Optimal nonpharmacological management of agitation in Alzheimer’s disease: challenges and solutions. Clin Interv Aging, 2016, 11: 175-184

[24] TekinS, MegaMS, MastermanDM, et al.. Orbitofrontal and anterior cingulate cortex neurofibrillary tangle burden is associated with agitation in Alzheimer disease. Ann Neurol, 2001, 49(3): 355-361

[25] MiladMR, RauchSL. The role of the orbitofrontal cortex in anxiety disorders. Ann N Y Acad Sci, 2007, 1121: 546-561

[26] Guzmán-VélezE, WarrenDE, FeinsteinJS, et al.. Dissociable contributions of amygdala and hippocampus to emotion and memory in patients with Alzheimer’s disease. Hippocampus, 2016, 26(6): 727-738

[27] YangC, LiX, GaoW, et al.. Cornel iridoid glycoside inhibits tau hyperphosphorylation via regulating cross-talk between GSK-3beta and PP2A signaling. Front Pharmacol, 2018, 9: 682

[28] DiJ, CohenLS, CorboCP, et al.. Abnormal tau induces cognitive impairment through two different mechanisms: synaptic dysfunction and neuronal loss. Sci Rep-UK, 2016, 6(1): 1-12

[29] HooverBR, ReedMN, SuJ, et al.. Tau mislocalization to dendritic spines mediates synaptic dysfunction independently of neurodegeneration. Neuron, 2010, 68(6): 1067-1081

[30] LiXG, HongXY, WangYL, et al.. Tau accumulation triggers STAT1-dependent memory deficits by suppressing NMDA receptor expression. EMBO Rep, 2019, 20(6): 1-18

[31] AlldredMJ, DuffKE, GinsbergSD. Microarray analysis of CA1 pyramidal neurons in a mouse model of tauopathy reveals progressive synaptic dysfunction. Neurobiol Dis, 2012, 45(2): 751-762

[32] ZinebiF, XieJ, LiuJ, et al.. NMDA currents and receptor protein are downregulated in the amygdala during maintenance of fear memory. J Neurosci, 2003, 23(32): 10283-10291

[33] KantrowitzJT, JavittDC. N-methyl-d-aspartate (NMDA) receptor dysfunction or dysregulation: The final common pathway on the road to schizophrenia?. Brain Res Bull, 2010, 83(3–4): 108-121

[34] ZhaiB, ShangX, FuJ, et al.. Rapamycin relieves anxious emotion and synaptic plasticity deficits induced by hindlimb unloading in mice. Neurosci Lett, 2018, 677: 44-48

[35] WangY, LiuQ, XieJ, et al.. Dcf1 affects memory and anxiety by regulating NMDA and AMPA receptors. Neurochem Res, 2019, 44(11): 2499-2505

[36] SilvaAJ, PaylorR, WehnerJM, et al.. Impaired spatial learning in alpha-calcium-calmodulin kinase II mutant mice. Science, 1992, 257(5067): 206-211

[37] StephensonJR, WangX, PerfittTL, et al.. A Novel Human CAMK2A Mutation Disrupts Dendritic Morphology and Synaptic Transmission, and Causes ASD-Related Behaviors. J Neurosci, 2017, 37(8): 2216-2233

[38] OgundeleOM, LeeCC. CaMKIIα expression in a mouse model of NMDAR hypofunction schizophrenia: Putative roles for IGF-1R and TLR4. Brain Res Bull, 2018, 137: 53-70

[39] NovakG, SeemanP. Hyperactive mice show elevated D2High receptors, a model for schizophrenia: Calcium/calmodulin-dependent kinase II alpha knockouts. Synapse, 2010, 64(10): 794-800

[40] YamagataY, KobayashiS, UmedaT, et al.. Kinase-dead knock-in mouse reveals an essential role of kinase activity of Ca2+/calmodulin-dependent protein kinase IIalpha in dendritic spine enlargement, long-term potentiation, and learning. J Neurosci, 2009, 29(23): 7607-7618

[41] HaltAR, DallapiazzaRF, ZhouY, et al.. CaMKII binding to GluN2B is critical during memory consolidation. EMBO J, 2012, 31(5): 1203-1216